RT Journal Article
SR Electronic
T1 Exploring the behavioural determinants of adherence to prescription for acute febrile illnesses, and development of a training and communication clinical trial intervention: a description of research methods
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.01.20240929
DO 10.1101/2020.12.01.20240929
A1 Horgan, Philip
A1 Salami, Olawale
A1 del Barrio, Mariam Otmani
A1 Tomar, Anjana
A1 Chadha, Sarabjit S
A1 Basnyat, Buddha
A1 Shakya, Summita Udas
A1 Kaawa-Magiri, David
A1 Hopkins, Heidi
A1 Kapisi, James
A1 Kukula, Vida
A1 Baiden, Rita
A1 Hlaing, Phyu Hnin
A1 Smithuis, Frank
A1 Campaore, Adelaide
A1 Tinto, Halidou
A1 Gautam, Manu
A1 Pathak, Ashish
A1 Kaur, Manmeet
A1 Taneja, Neelam
A1 Deb, Alok Kr.
A1 Dutta, Shanta
A1 Sahyog, Jan Swasthya
A1 Walia, Kamini
A1 Moore, Catrin E
A1 Olliaro, Piero
YR 2020
UL http://medrxiv.org/content/early/2020/12/04/2020.12.01.20240929.abstract
AB Objective To explore behavioural factors relating to prescription adherence and the communication of prescription adherence messages for patients with acute febrile illness, and to develop a Training & Communication (T&C) intervention to be delivered as part of a clinical trial. The clinical trial intervention package consists of improved diagnostic tools, clinical practices and the T&C package, for children, adolescents and adults presenting with fever symptoms at outpatient facilities in five LMICs.Design Content analysis of primary, qualitative data collection, informed by the Capability, Opportunity, Motivation (COM-B) theory of behaviour, the Theoretical Domains Framework (TDF) and Behaviour Change Wheel (BCW) approach.Setting Health facilities and local communities in five LMICs in Africa and Asia.Participants Health facility prescribers and local community adults.Intervention Febrile illness is a common presentation among adults and children in primary care settings, but diagnosing the cause of fever is challenging, especially in low-resource settings. Prescribers’ and patients’ behaviours underpin treatment practices, and antibiotics are the customary fallback choice for lack of better alternatives. However, in most cases antibiotics would not be required, do not cure the ongoing infection, and may have short-term (toxicity, costs) and long-term (drug resistance) untoward effects.Trialling new approaches including point-of-care tests and diagnostic algorithms alone would provide limited information on real-life applicability if behaviours are not accounted for.Accordingly, we designed an innovative, multiphase, mixed methods study, combining qualitative and behaviour approaches, with a quantitative two-arm, clinic based, randomised controlled trial. Qualitative and behavioural methods are used to: support the development of the Training & Communication component of the clinical trial, collect patient information on adherence, and support recommendations for future behaviour change interventions.This paper describes the qualitative research methods used to generate the clinical trial training and communication interventions, in support of adherence to prescriptions.Strengths and limitations of this studyThis is the first study we know of to explore the behavioural factors affecting prescription adherence and the communication of adherence messages in the LMIC study locations.The use of behavioural frameworks to shape the design of data gathering topic guides has the potential to illuminate the drivers for antibiotic prescription adherence, and generate the knowledge needed to support the design of effective communication interventions.The local nature of behavioural drivers means it is unlikely that the research findings will be generalisable and directly usable in other locations, however the process by which behavioural drivers are identified, and the process to convert to a training and communication package intervention, are applicable beyond the study sites.The scope of the clinical trial intervention, of which the T&C package is one component, precludes a wider behaviour change intervention which may be beneficial to improving adherence. This will be explored in a set of intervention recommendations.Because the T&C intervention is one component of the package of interventions for the clinical trial, we cannot rule out the influence of other intervention components (for example the use of an increased number of diagnostic tests) on prescription adherence. Similarly, due to the intervention ‘package’ approach, we cannot conclude how much the T&C package contributed to patient recovery at Day7, the primary outcome.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis paper describes the qualitative research undertaken to design one intervention of a clinical trial (ClinicalTrials.gov ID NCT0408105)Funding StatementThis work is supported by the Swiss Agency for Development and Cooperation, Global Health Division, Contract number 810571721 titled "Advancing access to better diagnostics for febrile childhood illnesses" and a Memorandum of Understanding between the UK Government Secretary of State for Health and Social Care and the Foundation for Innovative New Diagnostics (FIND). The Indian Council for Medical Research (ICMR) also contributes funds for the Indian study sites. The study funders have no role in data collection, interpretation and reporting. FIND is also using core funding and internal resources to manage the programme.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The overall protocol has been approved by the Oxford University TropicalResearch Ethics Committee (OxTREC number 52-19). Each of the country-specific protocols is also approved by national and/or institutional ethicscommittees in Burkina Faso, Ghana, Uganda, India and Nepal.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the study are availablefrom the corresponding author upon reasonable request.